Medytox's liquid non-animal botulinum toxin was rejected by the U.S. FDA.

COMPANY / Reporter Paul Lee / 2024-02-27 03:41:43
메디톡스. (사진=메디톡스)

 

[Alpha Biz=(Chicago) Reporter Paul Lee] Medytox announced on the 26th that the US Food and Drug Administration (FDA) refused to review the item license of the non-animal liquid botulinum toxin drug "MT10109L."

MT10109L is a liquid-type botulinum toxin drug designed to improve moderate and severe brow wrinkles and eye wrinkles.

Medytox applied for a product license for the product to FDA at the end of December last year, but FDA rejected the main review on the grounds that no specific verification test report was prepared regarding the substance.

Medytox said "We will discuss the matter with FDA and plan to supplement it and submit the application again."

Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)

어플

주요기사

Eastar Jet Founder Lee Sang-jik Acquitted in Hiring Irregularities Case on Appeal
SK & AWS Ulsan AI Data Center Plan Faces Delay as Ulsan Mipo Industrial Complex Excluded from Korea’s Distributed Energy Special Zone
Seoul High Prosecutors’ Office Launches Search of Ssangbangwool Group Subsidiary Amid Allegations of “Salmon & Soju Party” Witness Bribery in North-Korea Remittance Probe
National Pension Service of Korea to Support Elon Musk’s Compensation Package at Tesla; Opposes AI-Startup Investment Proposal
Hyundai Rotem Refutes Allegations of Supplying Faulty Locomotive Parts to Bangladesh
뉴스댓글 >

SNS